Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

NCT05567796 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05567796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05567796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 1, 2022
Completion date
October 19, 2026
Enrollment
3,400 (estimated)
Sites
256

Conditions

As the registry lists them; a condition with its own page is linked.

obesity